The Latest Breaking News from Eli Lilly

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones.

Pharmaceuticals giant Eli Lilly has formed a three-weeks tight pattern within the buy zone of flat base just before earnings.

Johnson & Johnson (NYSE: JNJ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades.

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

The Dow Jones Industrial Average fell Wednesday morning ahead of the highly-anticipated release of the minutes from last month's Fed meeting.

The Dow Jones Industrial Average dived 600 points Tuesday, as Tesla stock dropped on weaker-than-expected second quarter deliveries.

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 14 strange trades.

The Dow Jones Industrial Average rose Friday after the index staged its worst first-half performance since 1962. Chinese EV stocks reported strong sales.

The Dow Jones Industrial Average dived 575 points Thursday after a key inflation reading, threatening to extend this week's losses.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

The Dow Jones led the upside, while the Nasdaq and S&P 500 struggled to turn positive. Medical stocks continued to outperform.